Barclays PLC Has $973,000 Stake in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Barclays PLC boosted its position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 1,316.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 140,113 shares of the company's stock after purchasing an additional 130,219 shares during the period. Barclays PLC's holdings in GoodRx were worth $973,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in GDRX. Pier Capital LLC acquired a new stake in shares of GoodRx during the third quarter worth approximately $3,259,000. EP Wealth Advisors LLC acquired a new stake in GoodRx during the 3rd quarter valued at $73,000. Point72 Asset Management L.P. bought a new position in GoodRx in the 3rd quarter valued at $11,295,000. Centiva Capital LP boosted its stake in GoodRx by 27.5% in the third quarter. Centiva Capital LP now owns 66,233 shares of the company's stock worth $460,000 after purchasing an additional 14,287 shares in the last quarter. Finally, Rubric Capital Management LP boosted its stake in GoodRx by 25.2% in the third quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company's stock worth $32,479,000 after purchasing an additional 943,226 shares in the last quarter. 63.77% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently issued reports on GDRX. Citigroup cut their price target on GoodRx from $10.00 to $7.00 and set a "buy" rating for the company in a report on Wednesday, November 13th. Barclays dropped their target price on shares of GoodRx from $10.00 to $6.00 and set an "overweight" rating for the company in a research note on Monday, November 11th. Morgan Stanley decreased their price target on shares of GoodRx from $7.00 to $6.00 and set an "equal weight" rating on the stock in a research note on Tuesday, December 17th. Finally, Mizuho assumed coverage on shares of GoodRx in a research report on Wednesday, December 4th. They issued a "neutral" rating and a $5.00 price objective for the company. One research analyst has rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $8.37.

GoodRx Trading Up 3.1 %

Shares of GoodRx stock traded up $0.14 during trading on Tuesday, hitting $4.65. 1,136,538 shares of the company were exchanged, compared to its average volume of 1,417,009. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The firm has a market capitalization of $1.77 billion, a P/E ratio of -155.00, a price-to-earnings-growth ratio of 3.54 and a beta of 1.29. The firm's fifty day moving average price is $5.01 and its 200 day moving average price is $6.75. GoodRx Holdings, Inc. has a 1-year low of $4.09 and a 1-year high of $9.26.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.